Research Papers

25 of 259 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer.
Wu F; Wang M; Zhong T; Xiao C; Chen X; Huang Y; Wu M; Yu J; Chen D.
Exp Hematol Oncol (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy.
Zheng X; Jin X; Ye F; Liu X; Yu B; Li Z; Zhao T; Chen W; Liu X; Di C; Li Q.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malign…
Chen M; Liu X; Peng N; Zhang T; Mou J; He H; Wang Y; Xu Y; Xing H; Tang K; Tian Z; Rao Q; Gu R; Qiu S; Wang M; Wang J.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications.
Gu Y; Fang Y; Wu X; Xu T; Hu T; Xu Y; Ma P; Wang Q; Shu Y.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase …
Mao S; Yang S; Liu X; Li X; Wang Q; Zhang Y; Chen J; Wang Y; Gao G; Wu F; Jiang T; Zhang J; Yang Y; Lin X; Zhu X; Zhou C; Ren S.
Exp Hematol Oncol (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies.
Wang B; Liu Y; Liao Z; Wu H; Zhang B; Zhang L.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis…
Xin S; Liu X; Li Z; Sun X; Wang R; Zhang Z; Feng X; Jin L; Li W; Tang C; Mei W; Cao Q; Wang H; Zhang J; Feng L; Ye L.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The gut microbiota as a booster for radiotherapy: novel insights into radio-protection and radiation injury.
Yi Y; Lu W; Shen L; Wu Y; Zhang Z.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis.
Liu X; Zhong S; Qiu K; Chen X; Wu W; Zheng J; Liu Y; Wu H; Fan S; Nie D; Wang X; Yu Z; Liao Z; Zhong M; Li Y; Zeng C.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in rela…
Li W; Zhang B; Cao W; Zhang W; Li T; Liu L; Xu L; Gao F; Wang Y; Wang F; Xing H; Jiang Z; Shi J; Bian Z; Song Y.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
ANXA6/TRPV2 axis promotes lymphatic metastasis in head and neck squamous cell carcinoma by inducing autophagy.
Wang M; Pan M; Li Y; Lu T; Wang Z; Liu C; Hu G.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma.
Ma XL; Nie YY; Xie SH; Zheng H; Tong Y; Wang YC; Yan TQ; Meng X; Cao JZ; Tang WG; Guo L; Lu RQ.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell …
Wang HY; Yang FC; Yang CF; Liu YC; Ko PS; Li CJ; Tsai CK; Chung YL; Chen NJ.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma.
Chen Y; Yang P; Wang J; Gao S; Xiao S; Zhang W; Zhu M; Wang Y; Ke X; Jing H.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Characterization of bone marrow heterogeneity in NK-AML (M4/M5) based on single-cell RNA sequencing.
Wu W; Shi Z; Tang Z; Li H; Huang X; Liang X; Li J; Yao Y; Zhao W; Wu M; Luo J; Liu Z.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Emerging roles of m6A RNA modification in cancer therapeutic resistance.
Liu WW; Zhang ZY; Wang F; Wang H.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma.
Chen ZQ; Zuo XL; Cai J; Zhang Y; Han GY; Zhang L; Ding WZ; Wu JD; Wang XH.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
GPR109A controls neutrophil extracellular traps formation and improve early sepsis by regulating ROS/PAD4/Cit-H3 signal…
Guo W; Gong Q; Zong X; Wu D; Li Y; Xiao H; Song J; Zhang S; Fu S; Feng Z; Zhuang L.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Depletion of polyfunctional CD26<sup>high</sup>CD8<sup>+</sup> T cells repertoire in chronic lymphocytic leukemia.
Bozorgmehr N; Hnatiuk M; Peters AC; Elahi S.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Increasing cure rates of solid tumors by immune checkpoint inhibitors.
Ma W; Xue R; Zhu Z; Farrukh H; Song W; Li T; Zheng L; Pan CX.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspec…
Caracciolo D; Mancuso A; Polerà N; Froio C; D'Aquino G; Riillo C; Tagliaferri P; Tassone P.
Exp Hematol Oncol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches.
Hanel W; Herrera AF; Epperla N.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Increased expression of ECT2 predicts the poor prognosis of breast cancer patients.
Yi M; Zhang D; Song B; Zhao B; Niu M; Wu Y; Dai Z; Wu K.
Exp Hematol Oncol (Unknown)
Published: 2022
4/6 Transparent
Data Funding Declared
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and thera…
Dai M; Liu M; Yang H; Küçük C; You H.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia.
Zhou W; Yu J; Li Y; Wang K.
Exp Hematol Oncol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared